|All Peptides

Read the full guides

Cerebrolysin

Last reviewed: July 25, 2026 by The Peptide Catalog Team

A porcine-brain-derived mixture of low-molecular-weight peptides and amino acids given by injection, proposed to mimic neurotrophic factors (BDNF/GDNF/NGF-like); studied for stroke, TBI, and dementia with real but contested evidence, sold as a research chemical in the West. Cerebrolysin is a porcine-brain-derived neuropeptide mixture given by injection, studied for stroke, TBI, and dementia; evidence is real but contested.

Overview

Cerebrolysin Results Timeline

Progression
1
Days 1-10 (a course)
Physical Changes
Trial protocols run a daily IV/IM course; effects assessed at course end, not per-dose
Performance & Recovery
TBI (CAPTAIN) used 50 mL/day IV x10 days; AD meta used 30 mL/day (PMID 31494820, 25832905)
Other Benefits
Given by injection in impaired populations, not as a daily oral nootropic
2
Weeks 2-4 (clinical)
Physical Changes
AD meta-analysis reported cognitive/global-function benefit measured at ~4 weeks (clinical)
Performance & Recovery
Vascular-dementia trials reported cognition gains, but Cochrane called them 'not definitive'
Other Benefits
Outcomes are in dementia/stroke/TBI patients — not healthy-user enhancement (PMID 25832905, 31710397)
3
Repeat cycles
Physical Changes
Protocols repeat courses over months; durability of any effect is not well characterized
Performance & Recovery
CAPTAIN reported neurorecovery benefit after moderate-severe TBI over the trial window
Other Benefits
Community IM courses (~5-10 mL/day) are self-reported, not trial-validated
4
Honest read
Physical Changes
Stroke Cochrane found no benefit on death + a probable rise in non-fatal serious adverse events
Performance & Recovery
Evidence is genuinely mixed and much of it is manufacturer-associated (PMID 37818733)
Other Benefits
Not FDA-approved; injectable biologic — decisions belong with a licensed physician

Timeline is illustrative and non-guaranteed. Outcomes vary and are commonly discussed alongside training, nutrition, sleep, and cycling practices.

Read the full Cerebrolysin results timeline →

How It WorksPorcine-Brain-Derived Neuropeptide Mixture — Neurotrophic / Neuroprotective (Injectable; Not FDA-Approved; Contested Clinical Evidence)

Target → Signal → Effect → Outcomes

1
Target

A Mixture, Not a Single Molecule

Cerebrolysin is not one peptide. It is a preparation of low-molecular-weight peptides and free amino acids produced by controlled enzymatic breakdown of purified porcine (pig) brain proteins. The originally branded product is made in Austria; the standard concentrate is 215.2 mg/mL. The active fraction is proposed to be the small peptides that can cross the blood-brain barrier. Because it is a biologic mixture rather than a defined synthetic, batch composition and sourcing matter.

2
Cellular Signal

Mimics Neurotrophic Factors (BDNF/GDNF/NGF-like) — Proposed

The proposed mechanism (largely preclinical) is that the peptide fraction acts like endogenous neurotrophic factors — supporting neuronal survival, synaptic plasticity, and neuroprotection. An in vitro study reported that Cerebrolysin upregulated BDNF and Neuregulin 1 in neural cells under oxidative stress (PMID 38524067). These are mechanistic/preclinical signals, not a confirmed human mechanism.

3
Systemic Effect

Studied in Stroke, TBI, and Dementia — Mixed Results

Human evidence is real but contested. Meta-analysis reported cognitive and global-function benefit in mild-to-moderate Alzheimer's disease (PMID 25832905); the vascular-dementia Cochrane review reported improved cognition while calling the data "not definitive" (PMID 31710397); and the CAPTAIN trials reported benefit after moderate-severe TBI (PMID 31494820, 33620612). The acute-ischaemic-stroke Cochrane review, however, found no benefit on death and a probable increase in non-fatal serious adverse events (PMID 37818733).

4
What You Notice

Course-Based, in Clinical Populations

Cerebrolysin is given as injection courses (IV or IM) over 10-20 days, repeated in cycles — not a daily oral supplement. The documented outcomes are in impaired clinical populations (stroke, TBI, dementia) over weeks, not healthy-user enhancement. Community reports of cognitive benefit in healthy users are anecdotal and not placebo-controlled.

What Makes This Peptide Different

Cerebrolysin is unusual because it is a porcine-brain-derived biologic mixture given by injection, not a defined synthetic peptide — closer to a neurotrophic-factor extract than to compounds like Semax or Dihexa. It has a larger clinical-trial base than most research nootropics — decades of use across Russia, China, and Eastern Europe — but the evidence is genuinely contested: much of the supportive research is manufacturer-associated and regionally concentrated, and the Cochrane stroke review found a non-fatal serious-adverse-event signal. It is not FDA-approved in the US.

Cerebrolysin Vendors

No offers available at this time.

Dosing ProtocolStroke / TBI / Dementia / Cognition (Not FDA-Approved; Contested Evidence)

Educational reference only. Individual responses vary. Consult healthcare provider before use.

Vial Size
Multi-mL injection ampoules/vials (standard concentrate 215.2 mg/mL)
Reconstitution
Pre-mixed injectable solution — given by IM or IV, not reconstituted from a lyophilized powder
Dose
Trial courses used 10-50 mL/day IV; community sources report 5-10 mL/day IM
Timing
Once daily during a course
Frequency
Daily for a 10-20 day course, courses repeated in cycles
Duration
CAPTAIN TBI trials ran 50 mL/day IV x10 days, then two 10 mL/day x10-day cycles (PMID 31494820)
Protocol Notes
Porcine-brain-derived neuropeptide mixture (low-molecular-weight peptides + free amino acids). Not FDA-approved in the US. Trial doses vary by indication — AD meta-analysis used 30 mL/day IV (PMID 25832905), vascular-dementia trials ~20 mL/day, stroke trials up to 30-50 mL/day. The Cochrane stroke review found no benefit on death and flagged a probable increase in non-fatal serious adverse events (PMID 37818733). Community IM figures are self-reported, not trial-validated. Sold for research purposes only.

Why This Dosing Protocol

What doses were studied?Trial regimens are indication-specific: the Alzheimer's meta-analysis used 30 mL/day IV for at least four weeks (PMID 25832905), vascular-dementia trials used ~20 mL/day, and the CAPTAIN TBI protocol used 50 mL/day IV for 10 days followed by two 10 mL/day cycles (PMID 31494820). Cerebrolysin is dosed by volume (mL of the 215.2 mg/mL concentrate), not by mg like a potent peptide.

Route. It is a pre-mixed injectable solution given IM or IV — there is no bacteriostatic-water reconstitution step. Community sources self-report smaller IM courses (~5-10 mL/day), but those figures are not trial-validated. There is no established protocol for healthy cognitive enhancement.

Storage & Handling

Storage at a glance

Proper storage temperatures, shelf life, reconstitution best practices, and travel tips for lyophilized and reconstituted peptides.

Powder: Freezer
1+ year at -20°C
Reconstituted: Fridge
4 weeks max at 2-8°C
View Complete Storage Guide

Handling specifics

Educational overview on storage, labeling, and traceability considerations for lab environments. Consult primary literature and vendor documentation for specifics.

Powder storage (very stable)
  • Freezer (-20°C): 1+ year
  • Refrigerator (2-8°C): 1-3 months
  • Room temperature: 2-3 weeks (emergency only)
Reconstituted storage (fragile)
  • MUST refrigerate at 2-8°C
  • 4-week maximum shelf life
  • NEVER freeze after reconstitution
  • Use bacteriostatic water for multi-dose

FAQ

What is Cerebrolysin made of?

It is a mixture of low-molecular-weight peptides and free amino acids produced by controlled enzymatic breakdown of purified porcine (pig) brain proteins. It is not a single synthetic peptide — it is a biologic preparation proposed to mimic endogenous neurotrophic factors (BDNF/GDNF/NGF-like). Because it is porcine-derived, sourcing, purity, and batch consistency are real considerations.

Is Cerebrolysin FDA-approved?

No. Cerebrolysin is not approved by the FDA in the United States. The originally branded product is manufactured in Austria and is registered and used in Russia, China, and parts of Eastern Europe and Asia for stroke, traumatic brain injury, and dementia. In the West it is sold as a research chemical, not a medicine.

What does the clinical evidence actually show?

It is genuinely mixed. Meta-analyses have reported benefit in mild-to-moderate Alzheimer's disease (PMID 25832905) and the vascular-dementia Cochrane review reported improved cognition and global function, though it called the data "not definitive" (PMID 31710397). The Cochrane acute-ischaemic-stroke review, by contrast, found no beneficial effect on death and flagged a probable increase in non-fatal serious adverse events (PMID 37818733). Much of the supportive research is manufacturer-associated and concentrated in specific regions.

How is Cerebrolysin administered?

It is a pre-mixed injectable solution given by intramuscular or intravenous injection in courses — not a lyophilized vial reconstituted with bacteriostatic water. Trial courses used 10-50 mL/day by IV infusion for 10-20 days, repeated in cycles (PMID 31494820, 25832905). It is not taken orally. Decisions about an unapproved injectable are matters for a licensed physician.

How long does reconstituted peptide last?

Once mixed with bacteriostatic water, peptides remain stable for up to 4 weeks when refrigerated at 2-8°C (36-46°F). Unopened powder can last 1+ year in the freezer. Get our complete Storage & Travel Guide.

Is this peptide legal to purchase?

Peptides sold "for research purposes only" are legal to purchase in the US, but are not FDA-approved for human use outside of specific medical applications. Always consult a healthcare provider before use.

New to peptides?

Take our Peptide Match tool to find the best peptide for your goals. You can also read our Complete Guide to Peptides to learn the basics.

Cerebrolysin Research Articles

Disclosure: we may earn affiliate commission from qualifying purchases. Educational information only — not medical advice.